Drug Profile
Research programme: attention deficit hyperactivity disorder therapeutics - Advinus Therapeutics/P2D Bioscience
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Advinus Therapeutics; P2D Bioscience
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Attention-deficit hyperactivity disorder
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Attention-deficit-hyperactivity-disorder in India
- 16 Jul 2016 No recent reports of development identified for research development in Attention-deficit-hyperactivity-disorder in USA
- 24 Jul 2012 Early research in Attention-deficit hyperactivity disorder in India (unspecified route)